PCI Brexit Communication, 16 January 2019

The UK Parliament voted on 15th January 2019 rejecting the EU/UK Brexit deal and therefore, a number of unknown variables regarding the current Brexit situation remain.
As the position of Brexit evolves over the coming days and weeks, PCI expects to gain additional clarity and will be advising of any implications to supply chains.

PCI Pharma Services has a robust plan to ensure the continuity of EU supply chains; Including the acquisition of an EU facility (Millmount Healthcare), located near Dublin, Ireland with the construction of a Clinical Storage & Distribution facility and a full analytical release testing laboratory allowing method transfer for release of Commercial products.

Irrespective of the outcome, PCI Pharma Services is committed to ensuring that the security of supply chains and management will be maintained via our UK sites and our EU facility.

For further information, please contact the PCI Brexit team brexit@pciservices.com

Salim Haffar, CEO & President

When it comes to pharmaceutical and biopharmaceutical supply chain expertise who do you trust?

Your bridge between life-changing therapies and patients